Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Akouos has promoted Jennifer Wellman from senior vice president of regulatory and quality to chief operating officer. Additionally, Sachiyo Minegishi has been named chief financial officer of Akouos. Minegishi was most recently vice president and lead for sickle cell disease at bluebird bio.
ARCA biopharma has promoted Debra Marshall, the company’s senior vice president of medical affairs, to chief medical officer. In addition, ARCA promoted Sharon Perry from senior director of quality to the role of vice president of regulatory affairs and quality.
Kevin Eggan has been named head of research and early development at BioMarin Pharmaceutical. Eggan is a Harvard University professor and director of stem cell biology at the Stanley Center for Psychiatric Research at the Broad Institute.
CrystalGenomics has chosen Gavin Choy to be president of its subsidiary CG Pharmaceuticals. Choy most recently served as chief operating officer at Apollomics.
Crown Bioscience’s new vice president for global quality is Pam Shang, who comes to Crown from Japanese pharmaceutical Asahi Kasei America, where she was head of global quality and compliance.
Swedish biotech company Cyxone has hired Sally Abdelmoaty as its newest project manager for the company’s drug portfolio. Abdelmoaty was most recently a preclinical project manager at Kancera.
Gerard Michel has been named CEO of Delcath Systems. Michel was tapped from Vericel, where he served as chief financial officer and vice president of corporate development.
Elucida Oncology has named Eliel Bayever as the company’s new chief medical officer. Bayever most recently served as chief medical officer of OncoQuest Pharmaceuticals.
Renato Skerlj has taken the helm of San Diego-based biotech company Expansion Therapeutics as its new CEO and president. Prior to joining Expansion, Skerlj served as chief scientific officer for X4 pharmaceuticals.
Jack Bailey, former president of U.S. pharmaceuticals at GlaxoSmithKline, has been named the CEO of G1 Therapeutics.
Dietmar Aichhorn has been appointed chief operating officer of Hyloris Pharmaceuticals. Formerly, Aichhorn was involved in the clinical development program at Polpharma Biologics.
Suresh Durgam, former associate vice president of clinical development at Allergan, has been appointed chief medical officer of Intra-Cellular Therapies.
Pharmaceutical company Lipidor has named Anders Hagman as chief development officer. Hagman was previously head of development at Cobra Biologics.
Gerald O’Brien has been named vice president of pulmonary clinical development at Liquidia Technologies. O’Brien was most recently the vice president of development at Complexa.
Belén Garijo, current CEO of Merck Healthcare, will assume the role of CEO at Merck KGaA following the end of Stefan Oschmann’s tenure in April 2021.
Merck Research Laboratories
Dean Li, current senior vice president of discovery sciences and translational medicine at Merck Research Labs, will soon replace Roger Perlmutter as executive vice president and president of the Merck R&D division.
Abbas Kazimi has been appointed chief business officer of Nimbus Therapeutics. Kazimi was most recently the company’s director of business development.
Chief business officer of Nkarta, Nadir Mahmood, is assuming an expanded role that includes the title and responsibilities of chief financial and business officer. Prior to joining Nkarta, Mahmood was senior director of corporate development at Second Genome.
Jutta Wanner will join OS Therapies as chief technology officer and continue her work on the Next Generation Antibody Drug Conjugate technology she helped develop at BlinkBio.
Naveed Shams has been named chief scientific officer of ProQR Therapeutics. Prior to joining ProQR, Shams was senior corporate officer and head of global R&D and chief scientific officer at Santen.
Former president and founding executive of Imbrium Therapeutics, Paul Medeiros, has been named president and CEO of Q-State Biosciences.
Reven Holdings has recruited Nancy Oehlke to assume the role of manager of regulatory affairs and quality assurance. Oehlke has more than 20 years of experience in drug development and clinical research. Renae Townsend was named director of clinical operations at Reven, and Jenny Daniels has been appointed director of clinical quality assurance. Both Townsend and Daniels have more than 15 years of experience in clinical research and clinical monitoring.
The French company has announced its position of chief scientific officer will pass to Frank Nestle, previously the company’s global head of immunology and inflammation and chief scientific officer in North America. Nestle also will serve as Sanofi’s new head of research.
Shasqi has appointed Wayne Saville as chief medical officer. Saville comes to the company from a stint as vice president of oncology clinical development at Xencor.
Skyhawk Therapeutics has named Elliot Ehrich as chief medical officer and Joseph Duffy as senior vice president of chemistry. Ehrich was most recently a venture partner at 5AM Ventures and chief medical officer at Expansion Therapeutics, and Duffy previously held the role of executive director of discovery chemistry at Merck Research Laboratories.
Brian Roberts has been named CEO of Tarveda Therapeutics. Prior to Tarveda, Roberts was chief financial and operating officer at Avedro.
Thrive Earlier Detection
Thrive Earlier Detection has appointed Sam Asgarian to chief medical officer and Frank Diehl to executive vice president of product solutions. Asgarian was the former vice president of CVS Health’s Transformation Health Product organization, whereas Diehl most recently served as CEO of Sysmex Inostics.
Rupert Sandbrink has been named chief medical officer of Vico Therapeutics. Prior to this appointment, Sandbrink was chief development officer and chief medical officer at Topas Therapeutics.